M. Obrocea

发表

Antigen-targeted, synthetic vaccines for metastatic cancer

T. Kündig, A. Bot, D. Diamond, 2011 .

Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial

S. Raman, A. Ribas, J. Weber, 2011, Clinical Cancer Research.

A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors

J. Marshall, M. Ernstoff, N. Vogelzang, 2011, Journal of immunotherapy.

Cancer vaccines at an inflexion point: what next?

F. Marincola, A. Bot, M. Obrocea, 2011, Journal of Translational Medicine.

In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine.

F. Shirazi, D. Stewart, M. Obrocea, 1998, Oncology reports.

Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity

A. Bot, Z. Qiu, M. Obrocea, 2010, Journal of Translational Medicine.

Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma

E. Hersh, John Smith, J. Weber, 2008, Journal of immunotherapy.

Revisiting the paradigm on the putative need for antigen-specific responses in cancer

F. Marincola, A. Bot, M. Obrocea, 2015 .

Bidirectional Bedside Lab Bench Processes and Flexible Trial Design as a Means to Expedite the Development of Novel Immunotherapeutics

Adrian Bot, Mihail Obrocea, A. Bot, 2008 .

An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield.

S. Bates, F. Shirazi, C. Cripps, 2002, International journal of molecular medicine.